The Path to an RSV Vaccine

Shaw, Christine A.; Ciarlet, Max; Cooper, Brian; Dionigi, Lamberto; Keith, Paula; O’Brien, Kerry L.; Rafie-Kolpin, Maryam; Dormitzer, Philip R.

doi:10.21775/9781910190036.17

Cited by 5 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Estimations in the United Kingdom reported up to 18 000 hospitalizations and 8400 deaths caused by RSV per season with 79% of hospitalizations and 93% of deaths in persons older than 65 years . Several vaccine candidates against RSV are currently in early clinical development , and these vaccine candidates should also be tested in adults and the elderly. Vaccines against nosocomial pathogens such as Staphylococcus aureus , Clostridium difficile , Escherichia coli , Klebsiella pneumoniae , and Candida ssp .…”

Section: Immune Aging and Vaccinating The Elderlymentioning

confidence: 99%

Aging of the immune system: Focus on inflammation and vaccination

et al. 2016

View full text Add to dashboard Cite

Major advances in preventing, delaying or curing individual pathologies are responsible for an increasingly long life span in the developed parts of our planet, and indeed reaching 8–9 decades of life is nowadays extremely frequent. However, medical and sanitary advances have not prevented or delayed the underlying cause of the disparate pathologies occurring in the elderly: aging itself. The identification of the basis of the aging processes that drives the multiple pathologies and loss of function typical of older individuals is a major challenge in current aging research. Among the possible causes, an impairment of the immune system plays a major role, and indeed numerous studies have described immunological changes which occur with age. Far from the intention of being exhaustive, this review will focus on recent advances and views on the role that modifications of cell signalling and remodelling of the immune response play during human aging and longevity, paying particular attention to phenomena which are linked to the so called inflammaging process, such as dysregulation of innate immunity, altered T-cell or B-cell maturation and differentiation, as well as to the implications of immune aging for vaccination strategies in the elderly.

show abstract

Section: Immune Aging and Vaccinating The Elderlymentioning

confidence: 99%

Aging of the immune system: Focus on inflammation and vaccination

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Infections with RSV are one of the main causes of acute lower respiratory infections (ALRI) in children and the elderly worldwide, with an estimated 33.1 million cases and 3.2 million hospital admissions of children under five years of age in 2015 (Shi et al, 2017). Despite the urgent need to produce a safe and effective vaccine against RSV (Shaw et al, 2013a), none are currently available on the market. An unfortunate turn of events in the United States in the 1960s (Kim et al, 1969;Smatti et al, 2018) with an FI-RSV vaccine considerably slowed subsequent research in humans.…”

Section: Vaccines and Vaccine Candidates With Evidence Of Vaccine-ass...mentioning

confidence: 99%

Vaccine-associated enhanced disease in humans and animal models: Lessons and challenges for vaccine development

et al. 2022

View full text Add to dashboard Cite

The fight against infectious diseases calls for the development of safe and effective vaccines that generate long-lasting protective immunity. In a few situations, vaccine-mediated immune responses may have led to exacerbated pathology upon subsequent infection with the pathogen targeted by the vaccine. Such vaccine-associated enhanced disease (VAED) has been reported, or at least suspected, in animal models, and in a few instances in humans, for vaccine candidates against the respiratory syncytial virus (RSV), measles virus (MV), dengue virus (DENV), HIV-1, simian immunodeficiency virus (SIV), feline immunodeficiency virus (FIV), severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1), and the Middle East respiratory syndrome coronavirus (MERS-CoV). Although alleviated by clinical and epidemiological evidence, a number of concerns were also initially raised concerning the short- and long-term safety of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is causing the ongoing COVID-19 pandemic. Although the mechanisms leading to this phenomenon are not yet completely understood, the individual and/or collective role of antibody-dependent enhancement (ADE), complement-dependent enhancement, and cell-dependent enhancement have been highlighted. Here, we review mechanisms that may be associated with the risk of VAED, which are important to take into consideration, both in the assessment of vaccine safety and in finding ways to define models and immunization strategies that can alleviate such concerns.

show abstract

“…Szczepionka opracowana w latach 60. XX wieku opierająca się na inaktywowanym wirusie nasilała przebieg zakażenia RSV po naturalnym zachorowaniu, co spowodowało zaprzestanie jej stosowania [60]. Badania in vitro wskazywały, że przeciwciała skierowane przeciw glikoproteinie F skutecznie neutralizują wirusa, ale jednocześnie immunizacja zwierząt doświadczalnych nie prowadziła do uzyskania wysokiego poziomu przeciwciał mających tę zdolność.…”

Section: Odwrotna Wakcynologia 20unclassified

Współczesne Metody Identyfikacji Białkowych Antygenów Szczepionkowych

Jabłuszewski

Wyszyńska

2022

Postępy Mikrobiologii - Advancements of Microbiology

View full text Add to dashboard Cite

Streszczenie Postępy w genomice związane z ustawicznym sekwencjonowaniem kompletnych genomów drobnoustrojów, w tym mikroorganizmów patogennych, zrewolucjonizowały podejście do wyboru i projektowania antygenów szczepionkowych nowej generacji. Odwrócono klasyczny proces badawczy, ponieważ to zbiór danych genomowych stał się źródłem hipotez o immunogenności wytypowanych antygenów. W efekcie, możliwe jest wydajne przeanalizowanie tysięcy genów, niezależnie od poziomu ich ekspresji in vivo. Na tej podstawie typuje się pulę białkowych kandydatów, które można następnie poddać dalszym badaniom i dokładnie opisać ich epitopy powierzchniowe rozpoznawane przez elementy układu odpornościowego człowieka. Informacje o strukturze wybranego antygenu i jego interakcjach z układem immunologicznym mogą posłużyć do syntezy nowych cząsteczek, optymalizując czas i środki niezbędne do wprowadzenia do użytku nowego preparatu szczepionkowego.

show abstract

The Path to an RSV Vaccine

Cited by 5 publications

References 0 publications

Aging of the immune system: Focus on inflammation and vaccination

Aging of the immune system: Focus on inflammation and vaccination

Vaccine-associated enhanced disease in humans and animal models: Lessons and challenges for vaccine development

Współczesne Metody Identyfikacji Białkowych Antygenów Szczepionkowych

Contact Info

Product

Resources

About